Abstract: An electronic gaming device includes a cabinet including a front side. The cabinet defines an interior cavity and a slot on the front side providing access to the interior cavity. The gaming device further includes a bracket coupled to the cabinet and positioned within the interior cavity and a button deck coupled to the bracket and extending through the slot. The button deck includes a first transparent surface, a second transparent surface, and a transparent display panel positioned between the first transparent surface and the second transparent surface.

Abstract: The present invention relates to compounds that inhibit KRas G12D. In particular, the present invention relates to compounds that inhibit the activity of KRas G12D, pharmaceutical compositions comprising the compounds and methods of use therefor.

Abstract: Provided herein are compounds of the Formula I: and pharmaceutically acceptable salts, solvates and polymorphs thereof, wherein L, X1, R1, R2, R3, R4, R5 and R6 are as defined herein, for the treatment of BRAF-associated diseases and disorders, including BRAF-associated tumors, including malignant and benign BRAF-associated tumors of the CNS and malignant extracranial BRAF-associated tumors.

Abstract: Provided herein are compounds of the Formula I: and pharmaceutically acceptable salts, solvates and polymorphs thereof, wherein L, X1, R1, R2, R3, R4, R5 and R6 are as defined herein, for the treatment of BRAF-associated diseases and disorders, including BRAF-associated tumors, including malignant and benign BRAF-associated tumors of the CNS and malignant extracranial BRAF-associated tumors.

Abstract: Provided herein are compounds of the Formula I: and pharmaceutically acceptable salts, solvates and polymorphs thereof, wherein L, X1, R1, R2, R3, R4, R5 and R6 are as defined herein, for the treatment of BRAF-associated diseases and disorders, including BRAF-associated tumors, including malignant and benign BRAF-associated tumors of the CNS and malignant extracranial BRAF-associated tumors.

Abstract: A method for applying cannabidiol onto and into the skin is provided. The method includes applying cannabidiol onto skin and irradiating the skin and the cannabidiol with a laser light. The laser light has a wavelength ranging from 800 nm to 870 nm. The irradiating of the skin with the laser light results in at least some of the cannabidiol penetrating into the skin. The cannabidiol can be provided in a kit with a laser emitting tool.

Abstract: A method for applying cannabidiol onto and into the skin is provided. The method includes applying cannabidiol onto skin and irradiating the skin and the cannabidiol with a laser light. The laser light has a wavelength ranging from 800 nm to 870 nm. The irradiating of the skin with the laser light results in at least some of the cannabidiol penetrating into the skin. The cannabidiol can be provided in a kit with a laser emitting tool.

Abstract: Provided herein are compounds of the Formula I: and pharmaceutically acceptable salts, solvates and polymorphs thereof, wherein L, X1, R1, R2, R3, R4, R5 and R6 are as defined herein, for the treatment of BRAF-associated diseases and disorders, including BRAF-associated tumors, including malignant and benign BRAF-associated tumors of the CNS and malignant extracranial BRAF-associated tumors.

Abstract: An optical display element of one embodiment of the invention is disclosed that comprises a binary optical display element and a multiple-bit storage element to store a number of bits of a color intensity value to be displayed by the binary optical display element during a display period. Each bit is loaded from the multiple-bit storage element into the binary optical display element one or more times during the display period to achieve the color intensity value.